Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Unlocking the genetic roots of fibromyalgia's pain puzzle

NCT ID NCT04624581

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This study investigates whether genetic differences and altered pain processing contribute to fibromyalgia, a condition marked by widespread pain and increased sensitivity to painful stimuli. Researchers will compare 260 adults with fibromyalgia to a matched control group, measuring pain thresholds via a nerve reflex test and analyzing genetic variations. The goal is to better understand the biological mechanisms behind fibromyalgia, which could inform future diagnostic or treatment strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electrophysiological measurement of reflex nociceptive flexion threshold (RIII reflex) using Nicolet Vicking device
What this could lead to
If successful, this research could uncover genetic markers that help explain why fibromyalgia develops, potentially leading to more personalized diagnosis or treatment approaches.
What could go wrong
This is an observational study, so it won't test a treatment. The findings may not directly translate into new therapies, and genetic associations may be complex and require further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

260 people

The number who actually took part.

Started

Nov 2020

Finished

Jan 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion criteria : * Patient between 18 and 65 years old (included), * Patient with fibromyalgia according to the criteria of the 2016 ACR, * Patient weighing more than 45kg * Cooperation and understanding sufficient to comply with the requirements of the study, * Acceptance to give written consent, * Affiliation to the French Social Security system, Patient exclusion criteria : * treated with antibiotics in the three months prior to inclusion, * who has reported gastroenteritis in the two months prior to inclusion, * having a medical and / or surgical history judged by the investigator or his representative to be incompatible with the test * of childbearing age not using an effective contraceptive method, pregnant or breastfeeding woman. * participating in another clinical trial, or being in the exclusion period, or having received a total amount of benefits exceeding EUR 4500 over the 12 months preceding the start of the trial, * benefiting from a measure of legal protection (guardianship, guardianship, deprivation of liberty, safeguard of justice), Subject inclusion criteria: * Aged of more than 18 years, * weighing more than 45kg * non-painful subjects matched by age (+/- 5 years), by sex, and by menopausal status for women, * Cooperation and understanding sufficient to comply with the requirements of the study, * Acceptance of written consent, * Affiliation to the French Social Security system, * Registration or acceptance of registration in the National Register of Volunteers participating in research. Subject exclusion criteria : * treated with antibiotics in the three months prior to inclusion, * who has reported gastroenteritis in the two months prior to inclusion, * Medical and / or surgical history judged by the investigator or his representative to be incompatible with the test, * Intake of any drugs in the 7 days before inclusion, * Pregnant or nursing woman * Participating in another clinical trial, or within the exclusion period, or having received a total amount of compensation in excess of EUR 4500 over the 12 months preceding the start of the trial, * Benefiting from a measure of legal protection (curatorship, guardianship, safeguard of justice ...)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain fibromyalgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, 63000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.